Monisha Singh, MD

Instructor in Medicine, Academic Institute
Houston Methodist
Weill Cornell Medical College


Education & Training

Clinical Fellowship, LAC-Olive View/UCLA Medical Center
Residency, LAC-Harbor-UCLA Medical Center
Internship, LAC-Harbor-UCLA Medical Center
MD, University of California at Los Angeles School of Medicine
Publications

Impact of Infections in Patients Receiving Pembrolizumab-Based Therapies for Non-Small Cell Lung Cancer: Cancers
Burns, EA, Gee, K, Kieser, RB, Xu, J, Zhang, Y, Crenshaw, A, Muhsen, IN, Mylavarapu, C, Esmail, A, Shah, S, Umoru, G, Sun, K, Guerrero, C, Gong, Z, Heyne, K, Singh, M, Zhang, J, Bernicker, EH & Abdelrahim, M 2023, . Cancers. https://doi.org/10.3390/cancers15010081

1234 Impact of infections in patients receiving immune checkpoint inhibitor therapies for non-small cell lung cancer (NSCLC)
Gee, K, Wiechmann, C, Burns, EA, Xu, J, Zhang, Y, Esmail, A, Crenshaw, A, Kieser, RB, Umoru, G, Muhsen, I, Sun, K, Gong, Z, Shah, S, Singh, M, Zhang, J, Bernicker, E & Abdelrahim, M 2023, , Journal for immunotherapy of cancer, vol. 11, no. Suppl 1, pp. A1361-A1361. https://doi.org/10.1136/jitc-2023-SITC2023.1234

1233 Impact of infections occurring in patients receiving immune checkpoint inhibitors for renal cell carcinoma (RCC)
Wiechmann, C, Gee, K, Burns, EA, Xu, J, Zhang, Y, Crenshaw, A, Esmail, A, Kieser, RB, Umoru, G, Muhsen, I, Sun, K, Gong, Z, Shah, S, Singh, M, Zhang, J, Efstathiou, E & Abdelrahim, M 2023, , Journal for immunotherapy of cancer, vol. 11, no. Suppl 1, pp. A1360-A1360. https://doi.org/10.1136/jitc-2023-SITC2023.1233

Impact of Infections in Patients Receiving Pembrolizumab-Based Therapies for Non-Small Cell Lung Cancer
Burns, EA, Gee, K, Kieser, RB, Xu, J, Zhang, Y, Crenshaw, A, Muhsen, IN, Mylavarapu, C, Esmail, A, Shah, S, Umoru, G, Sun, K, Guerrero, C, Gong, Z, Heyne, K, Singh, M, Zhang, J, Bernicker, EH & Abdelrahim, M 2022, , Cancers, vol. 15, no. 1. https://doi.org/10.3390/cancers15010081

Impact of Infections in Patients Receiving Pembrolizumab-Based Therapies for Non-Small Cell Lung Cancer
Burns, EA, Gee, K, Kieser, RB, Xu, J, Zhang, Y, Crenshaw, A, Muhsen, IN, Mylavarapu, C, Esmail, A, Shah, S, Umoru, G, Sun, K, Guerrero, C, Gong, Z, Heyne, K, Singh, M, Zhang, J, Bernicker, EH & Abdelrahim, M 2022, , Cancers, vol. 15, no. 1, 81. https://doi.org/10.3390/cancers15010081, https://doi.org/10.3390/cancers15010081

480 Impact of infections in patients with advanced or metastatic non-small cell lung cancer (NSCLC) receiving pembrolizumab-based therapies
Burns, EA, Xu, J, Kieser, R, Muhsen, I, Shah, S, Umoru, G, Mylavarapu, C, Zhang, Y, Crenshaw, A, Sun, K, Esmail, A, Guerrero, C, Gong, Z, Gee, K, Heyne, K, Singh, M, Zhang, J, Bernicker, E & Abdelrahim, M 2022, , J Immunother Cancer, vol. 10, no. Suppl 2, pp. A501. https://doi.org/10.1136/jitc-2022-SITC2022.0480

Infections and their impact on patients on pembrolizumab-based therapies for head and neck cancer. Journal of Clinical Oncology
Zhang, Y, Xu, J, Muhsen, I, Burns, EA, Shah, SM, Umoru, G, Mylavarapu, C, Sun, K, Crenshaw, A, Esmail, A, Kieser, RB, Guerrero, C, Gong, Z, Gee, K, Heyne, K, Singh, M, Zhang, J & Abdelrahim, M 2022, , Journal of Clinical Oncology, vol. 40, no. 16_suppl, pp. 6035.

Outcomes of patients with advanced urothelial cancer who develop infection while on treatment with pembrolizumab. Journal of Clinical Oncology
Kieser, RB, Xu, J, Burns, EA, Muhsen, I, Shah, SM, Umoru, G, Mylavarapu, C, Sun, K, Zhang, Y, Crenshaw, A, Esmail, A, Guerrero, C, Gong, Z, Gee, K, Heyne, K, Singh, M, Zhang, J, Efstathiou, E, Bernicker, E & Abdelrahim, M 2022, , Journal of Clinical Oncology, vol. 40, no. 16_suppl, pp. 4573. https://doi.org/10.1200/JCO.2022.40.16_suppl.4573

Successful treatment of a stage IIIC small-cell carcinoma of the ovary hypercalcemic subtype using multi-modality therapeutic approach
Qin, Q, Ajewole, VB, Sheu, TG, Donohue, R & Singh, M 2018, , ecancermedicalscience, vol. 12, 832. https://doi.org/10.3332/ecancer.2018.832